# Fair Underwriting - Competitive Analysis

**Last Updated**: November 7, 2025
**Analysis Type**: Market Positioning & Competitive Intelligence
**Status**: Active Market Research

---

## Executive Summary

Fair Underwriting operates in a **unique market position** at the intersection of genetic testing, insurance wellness programs, and privacy protection. While there are competitors in adjacent spaces, **no direct competitors exist** with our specific combination of:

1. **Patent-protected privacy framework** (post-policy genetic testing)
2. **B2B2C insurance partnership model** (insurer-sponsored, customer-private)
3. **Focus on SERPINA1/AATD** with MZ carrier detection
4. **Privacy-first architecture** preventing actuarial discrimination

**Key Finding**: Our primary competition is **customer inertia and genetic privacy fears**, not other companies.

---

## Competitive Landscape Overview

### Market Segmentation

```
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ                    GENETIC TESTING MARKET                    ‚îÇ
‚îú‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î§
‚îÇ                                                               ‚îÇ
‚îÇ  Direct-to-Consumer (DTC)          B2B/Clinical              ‚îÇ
‚îÇ  ‚îú‚îÄ 23andMe                        ‚îú‚îÄ Quest/LabCorp          ‚îÇ
‚îÇ  ‚îú‚îÄ AncestryDNA                    ‚îú‚îÄ Invitae                ‚îÇ
‚îÇ  ‚îú‚îÄ Color Genomics                 ‚îî‚îÄ GeneDx                 ‚îÇ
‚îÇ  ‚îî‚îÄ Nebula Genomics                                          ‚îÇ
‚îÇ                                                               ‚îÇ
‚îÇ  Disease-Specific                   Insurance Wellness        ‚îÇ
‚îÇ  ‚îú‚îÄ AlphaNet (AATD)                ‚îú‚îÄ Virgin Pulse           ‚îÇ
‚îÇ  ‚îú‚îÄ Alpha-1 Foundation             ‚îú‚îÄ Wellable               ‚îÇ
‚îÇ  ‚îî‚îÄ COPD Foundation                ‚îî‚îÄ Omada Health           ‚îÇ
‚îÇ                                                               ‚îÇ
‚îÇ              üéØ FAIR UNDERWRITING                            ‚îÇ
‚îÇ         (Unique intersection of all four)                     ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
```

---

## Direct-to-Consumer Genetic Testing Companies

### 1. 23andMe

**Overview**:

- Founded: 2006
- Valuation: ~$1B (post-SPAC decline from $6B)
- Model: DTC genetic testing ($99-$229)
- Users: 12+ million

**Products**:

- Ancestry + Health ($229)
- Health-only ($199)
- 23andMe+ Premium ($229/year membership)

**Genetic Tests Covered**:

- 10+ health predisposition reports (BRCA1/BRCA2, late-onset Alzheimer's, etc.)
- Carrier status for 40+ conditions
- Pharmacogenetics
- Wellness traits
- **Does NOT include SERPINA1/AATD testing**

**Privacy Model**:

- Customer owns data
- Opt-in for research
- Has sold data access to pharma companies (controversial)
- No special insurance protections

**Strengths**:

- ‚úÖ Brand recognition and trust
- ‚úÖ Large existing customer base
- ‚úÖ Comprehensive ancestry + health
- ‚úÖ FDA-approved health reports

**Weaknesses**:

- ‚ùå Privacy concerns (data selling)
- ‚ùå No insurance partnerships
- ‚ùå No AATD/SERPINA1 testing
- ‚ùå No genetic counseling included
- ‚ùå Declining revenue and user growth

**Fair Underwriting Differentiation**:

- ‚úÖ We include SERPINA1/AATD (they don't)
- ‚úÖ Insurance partnership model (they're DTC only)
- ‚úÖ Patent-protected privacy framework
- ‚úÖ Genetic counseling included
- ‚úÖ Focus on actionable health risks (MZ = 2-3% of population)

---

### 2. AncestryDNA

**Overview**:

- Founded: 1983 (DNA testing: 2012)
- Parent: Blackstone Group (private equity, acquired 2020)
- Model: DTC genetic testing + genealogy
- Users: 20+ million DNA tests sold

**Products**:

- AncestryDNA ($99)
- AncestryDNA + Traits ($119)
- Ancestry subscription (genealogy research, $25-50/month)

**Genetic Tests Covered**:

- Ancestry and ethnicity
- DNA matching with relatives
- Genetic traits (wellness, appearance)
- **NO comprehensive health reports**
- **NO SERPINA1/AATD testing**

**Privacy Model**:

- Customer owns data
- Complex privacy settings
- Historical privacy controversies (law enforcement access)

**Strengths**:

- ‚úÖ Largest DNA database
- ‚úÖ Strong genealogy platform
- ‚úÖ Brand trust in ancestry space

**Weaknesses**:

- ‚ùå Not health-focused
- ‚ùå No AATD testing
- ‚ùå No insurance model
- ‚ùå Privacy concerns

**Fair Underwriting Differentiation**:

- ‚úÖ Health-focused vs. ancestry-focused
- ‚úÖ Clinical-grade AATD testing
- ‚úÖ Insurance wellness integration

---

### 3. Color Genomics

**Overview**:

- Founded: 2013
- Funding: $278M raised
- Model: Clinical-grade genetic testing (B2B2C and DTC)
- Focus: Cancer and cardiac health

**Products**:

- Color Standard ($249): BRCA1/2, Lynch syndrome, cardiac conditions
- Color Extended ($399): 74 genes
- Hereditary Cancer Test (30 genes)
- Hereditary Heart Health Test (30 genes)

**Partnerships**:

- Employer wellness programs
- Health systems
- Some insurance partnerships

**Genetic Tests Covered**:

- Cancer predisposition (BRCA, Lynch, etc.)
- Cardiac conditions (familial hypercholesterolemia, etc.)
- Pharmacogenetics
- **Does NOT include SERPINA1/AATD**

**Privacy Model**:

- HIPAA-compliant
- Clinical-grade lab (CLIA/CAP certified)
- Genetic counseling included
- No data selling

**Strengths**:

- ‚úÖ Clinical-grade testing
- ‚úÖ Employer/health system partnerships
- ‚úÖ Genetic counseling included
- ‚úÖ Strong medical credibility

**Weaknesses**:

- ‚ùå Focus on cancer/cardiac only
- ‚ùå No AATD testing
- ‚ùå No insurance-specific privacy protections
- ‚ùå Higher price point ($250-400)

**Fair Underwriting Differentiation**:

- ‚úÖ AATD/SERPINA1 focus (unmet need)
- ‚úÖ Patent-protected insurance privacy
- ‚úÖ MZ detection (1 in 25-40 vs. BRCA 1 in 400)
- ‚úÖ Broader population applicability

---

### 4. Nebula Genomics

**Overview**:

- Founded: 2016 (by George Church, Harvard geneticist)
- Model: Privacy-focused DTC whole genome sequencing
- Focus: Blockchain-based data ownership

**Products**:

- 30x Whole Genome Sequencing ($249)
- Deep Whole Genome Sequencing ($999, 100x coverage)

**Privacy Model**:

- Blockchain data storage
- Customer owns and controls all data
- Can sell anonymized data to researchers
- Privacy-first marketing

**Genetic Tests Covered**:

- Whole genome (comprehensive)
- Ancestry
- Health predispositions
- Traits
- **Includes SERPINA1** (as part of whole genome)

**Strengths**:

- ‚úÖ Privacy-focused
- ‚úÖ Comprehensive genome coverage
- ‚úÖ Blockchain innovation
- ‚úÖ Includes SERPINA1

**Weaknesses**:

- ‚ùå No insurance partnerships
- ‚ùå DTC only (no B2B model)
- ‚ùå No specific AATD focus or counseling
- ‚ùå Complex interpretation (customer responsible)
- ‚ùå Higher price point
- ‚ùå Small market share

**Fair Underwriting Differentiation**:

- ‚úÖ Insurance partnership model (they're DTC)
- ‚úÖ Focused AATD interpretation and counseling
- ‚úÖ Patent-protected privacy (legal vs. technical)
- ‚úÖ B2B2C economics (free to customer via insurer)

---

## Clinical Laboratory Testing Companies

### 5. Quest Diagnostics

**Overview**:

- Founded: 1967
- Market Cap: $18B (NYSE: DGX)
- Model: Clinical laboratory services (physician-ordered)
- Revenue: $9.4B (2023)

**AATD Testing**:

- ‚úÖ **Offers SERPINA1 gene testing** (physician-ordered)
- ‚úÖ AAT serum level testing
- ‚úÖ Phenotyping
- Clinical-grade, CLIA-certified
- Requires physician order

**Pricing**:

- SERPINA1 genotyping: $150-300 (insurance billed)
- AAT level: $30-80
- Usually covered by insurance with appropriate diagnosis codes

**Strengths**:

- ‚úÖ Clinical credibility
- ‚úÖ Insurance reimbursement
- ‚úÖ Physician integration
- ‚úÖ CLIA/CAP certified
- ‚úÖ Already offers AATD testing

**Weaknesses**:

- ‚ùå Requires physician order (barrier)
- ‚ùå No consumer access
- ‚ùå No wellness/prevention model
- ‚ùå No insurance partnership for privacy protection
- ‚ùå Results go to physician (insurance may see)

**Fair Underwriting Differentiation**:

- ‚úÖ Direct insurance partnerships (no physician order needed)
- ‚úÖ Preventive/wellness model vs. diagnostic
- ‚úÖ Privacy protection (insurer can't access genetic results)
- ‚úÖ Genetic counseling and education included
- ‚úÖ Proactive vs. reactive (test before symptoms)

**Partnership Opportunity**: Quest could be our lab partner (not competitor)

---

### 6. LabCorp (Labcorp Diagnostics)

**Overview**:

- Founded: 1971
- Market Cap: $17B (NYSE: LH)
- Model: Clinical laboratory services
- Revenue: $16.1B (2023)

**AATD Testing**:

- ‚úÖ **Offers SERPINA1 gene sequencing**
- ‚úÖ AAT quantitation
- ‚úÖ Phenotyping
- Clinical-grade
- Requires physician order

**Strengths & Weaknesses**: Similar to Quest

**Fair Underwriting Differentiation**: Same as Quest

**Partnership Opportunity**: LabCorp could be our lab partner (not competitor)

---

### 7. Invitae

**Overview**:

- Founded: 2010
- Status: Bankrupt (2023), acquired by Labcorp (2024)
- Model: Clinical genetic testing (B2B2C)
- Focus: Hereditary cancer, cardiology, neurology

**Products**:

- Multi-gene panels ($250)
- Whole exome sequencing
- Proactive genetic screening

**AATD Testing**:

- Included in some comprehensive panels
- Not a focus area

**Strengths**:

- ‚úÖ Clinical-grade
- ‚úÖ Broad gene coverage
- ‚úÖ Genetic counseling

**Weaknesses**:

- ‚ùå Bankrupt/acquired (execution risk)
- ‚ùå No insurance privacy model
- ‚ùå AATD not a focus

**Fair Underwriting Differentiation**:

- ‚úÖ AATD-specific expertise
- ‚úÖ Insurance partnership model
- ‚úÖ Privacy-first vs. clinical diagnostic focus

---

## Disease-Specific Organizations

### 8. AlphaNet

**Overview**:

- Founded: 1995 (by Grifols, plasma products company)
- Model: Disease management for AATD patients
- Non-profit status, but Grifols-funded
- Focus: ZZ patients (severe AATD)

**Services**:

- Disease management coordinators
- Alpha-1 testing (free if uninsured)
- Augmentation therapy support
- Patient education
- Research registry

**Testing**:

- ‚úÖ **Free SERPINA1 genetic testing** (for uninsured)
- ‚úÖ Free AAT level testing
- Partners with labs
- Focus on diagnosis, not prevention

**Target Audience**:

- Diagnosed or suspected AATD patients
- Symptomatic individuals (COPD, liver disease)
- Family members of ZZ patients

**Strengths**:

- ‚úÖ Free testing
- ‚úÖ Disease expertise
- ‚úÖ Patient support services
- ‚úÖ Established in AATD community

**Weaknesses**:

- ‚ùå Focus on severe (ZZ) cases, not MZ
- ‚ùå Not prevention-focused
- ‚ùå Grifols conflict of interest (sells augmentation therapy)
- ‚ùå No insurance wellness model
- ‚ùå No privacy protection from insurers

**Fair Underwriting Differentiation**:

- ‚úÖ **MZ focus** (1 in 25-40) vs. ZZ focus (1 in 2,500)
- ‚úÖ Prevention model vs. disease management
- ‚úÖ Asymptomatic screening vs. symptomatic testing
- ‚úÖ Insurance partnership with privacy protection
- ‚úÖ No conflict of interest (we don't sell treatments)

**Relationship**: Potential partner for patient referrals (ZZ cases we detect)

---

### 9. Alpha-1 Foundation

**Overview**:

- Founded: 1995
- Model: Non-profit advocacy and research
- Focus: AATD awareness, research funding, patient support

**Services**:

- Research grants
- Patient education
- Advocacy
- Testing programs (various partnerships)
- Community support

**Testing**:

- Coordinates free/low-cost testing programs
- Partners with AlphaNet, labs, research studies
- Focus on increasing diagnosis rates

**Strengths**:

- ‚úÖ Non-profit credibility
- ‚úÖ Research funding
- ‚úÖ Patient community
- ‚úÖ Medical professional education

**Weaknesses**:

- ‚ùå Not a testing provider
- ‚ùå Limited prevention focus
- ‚ùå No insurance model

**Fair Underwriting Differentiation**:

- ‚úÖ Commercial model (sustainable, scalable)
- ‚úÖ Insurance partnership structure
- ‚úÖ Technology platform vs. coordination

**Relationship**: Potential partner for education, advocacy, medical advisor recruitment

---

## Insurance Wellness & Digital Health Companies

### 10. Virgin Pulse (part of Gympass)

**Overview**:

- Founded: 2004
- Acquired by Gympass (2023)
- Model: Corporate wellness platform
- Clients: 14M+ members, enterprise customers

**Services**:

- Activity tracking (steps, exercise)
- Challenges and gamification
- Health assessments
- Biometric screenings
- Rewards programs

**Genetic Testing**:

- ‚ùå **Does NOT include genetic testing**
- Focus on behavior change, activity, nutrition

**Strengths**:

- ‚úÖ Large enterprise client base
- ‚úÖ Engagement platform
- ‚úÖ Insurance partnerships

**Weaknesses**:

- ‚ùå No genetic testing
- ‚ùå No clinical diagnostics
- ‚ùå Surface-level health data

**Fair Underwriting Differentiation**:

- ‚úÖ Genetic health insights vs. activity tracking
- ‚úÖ Clinical-grade testing
- ‚úÖ Actionable disease prevention (MZ)

**Partnership Opportunity**: Could integrate Fair Underwriting as genetic wellness add-on

---

### 11. Omada Health

**Overview**:

- Founded: 2011
- Funding: $256M raised
- Model: Digital therapeutics for chronic disease prevention
- Focus: Diabetes, hypertension, MSK

**Services**:

- Digital health coaching
- Connected devices (scale, BP monitor)
- Behavior change programs
- Employer/health plan partnerships

**Genetic Testing**:

- ‚ùå **No genetic testing**

**Strengths**:

- ‚úÖ Clinical outcomes proven
- ‚úÖ Insurance partnerships
- ‚úÖ Reimbursement model

**Weaknesses**:

- ‚ùå No genetic insights
- ‚ùå Focus on common conditions (diabetes, BP)

**Fair Underwriting Differentiation**:

- ‚úÖ Genetic prevention vs. lifestyle intervention
- ‚úÖ Underserved condition (AATD/MZ)
- ‚úÖ Privacy-protected data

**Partnership Opportunity**: Complementary services (lifestyle coaching for MZ carriers)

---

### 12. Wellable

**Overview**:

- Founded: 2012
- Model: Wellness platform for employers
- Focus: Activity, nutrition, mental health

**Services**:

- Wellness challenges
- Integration with fitness trackers
- Biometric screening coordination
- Employee engagement

**Genetic Testing**:

- ‚ùå **No genetic testing**

**Fair Underwriting Differentiation**:

- ‚úÖ Genetic health component
- ‚úÖ Clinical-grade insights

**Partnership Opportunity**: Platform integration

---

## Competitive Matrix

| Company               | SERPINA1 Testing | MZ Focus    | Privacy Protection | Insurance Model | Counseling  | Price                       | Market Position      |
| --------------------- | ---------------- | ----------- | ------------------ | --------------- | ----------- | --------------------------- | -------------------- |
| **Fair Underwriting** | ‚úÖ Core          | ‚úÖ Yes      | ‚úÖ Patent          | ‚úÖ B2B2C        | ‚úÖ Included | Free (B2B) / $150-250 (DTC) | **Unique**           |
| 23andMe               | ‚ùå No            | ‚ùå No       | ‚ö†Ô∏è Basic           | ‚ùå No           | ‚ùå No       | $199-229                    | DTC Genetic          |
| AncestryDNA           | ‚ùå No            | ‚ùå No       | ‚ö†Ô∏è Basic           | ‚ùå No           | ‚ùå No       | $99-119                     | DTC Ancestry         |
| Color Genomics        | ‚ùå No            | ‚ùå No       | ‚úÖ HIPAA           | ‚ö†Ô∏è Some         | ‚úÖ Yes      | $249-399                    | Clinical Cancer      |
| Nebula Genomics       | ‚úÖ Part of WGS   | ‚ùå No       | ‚úÖ Blockchain      | ‚ùå No           | ‚ùå No       | $249-999                    | DTC Privacy          |
| Quest/LabCorp         | ‚úÖ Clinical      | ‚ùå No       | ‚ùå No              | ‚ùå No           | ‚ùå No       | $150-300                    | Clinical Lab         |
| Invitae               | ‚ö†Ô∏è Panel         | ‚ùå No       | ‚úÖ HIPAA           | ‚ùå No           | ‚úÖ Yes      | $250                        | Clinical Multi-gene  |
| AlphaNet              | ‚úÖ Free          | ‚ö†Ô∏è ZZ Focus | ‚ùå No              | ‚ùå No           | ‚úÖ Yes      | Free                        | Disease Mgmt         |
| Alpha-1 Foundation    | ‚ö†Ô∏è Coordinates   | ‚ùå No       | ‚ùå No              | ‚ùå No           | ‚ö†Ô∏è Some     | Varies                      | Advocacy             |
| Virgin Pulse          | ‚ùå No            | ‚ùå No       | N/A                | ‚úÖ Wellness     | ‚ùå No       | Enterprise                  | Wellness Platform    |
| Omada Health          | ‚ùå No            | ‚ùå No       | N/A                | ‚úÖ Health Plan  | ‚úÖ Coaching | Enterprise                  | Digital Therapeutics |

---

## Competitive Advantages Summary

### 1. **Patent Protection** üèÜ

- **Only player** with legal framework for post-policy genetic testing
- **Claim 34** prevents insurance discrimination
- **Defensible moat** (10+ years patent life)

### 2. **MZ Focus** üéØ

- **1 in 25-40 prevalence** vs. competitors' rare diseases (1 in 400-2,500)
- **Actionable health risk** requiring intervention
- **Underserved market** (>95% undiagnosed)

### 3. **B2B2C Model** üíº

- **Insurance partnerships** (not DTC)
- **Free to customer** (insurer-paid)
- **Privacy guarantee** (customer owns data, insurer can't access)
- **Win-win-win** (customer, insurer, Fair Underwriting)

### 4. **Clinical Focus** üî¨

- **AATD-specific expertise** vs. general genetic testing
- **Genetic counseling included** (not add-on)
- **Actionable results** (lifestyle, monitoring, family screening)

### 5. **Privacy-by-Design** üîê

- **5-level data segregation**
- **Genetic Data Vault** (isolated infrastructure)
- **Legal + technical** protection (patent + architecture)

---

## Competitive Threats & Mitigation

### Threat 1: DTC Genetic Companies Add AATD

**Risk**: 23andMe, Color, or others add SERPINA1 testing
**Likelihood**: Medium (low priority for them)
**Impact**: Medium

**Mitigation**:

- ‚úÖ Our B2B2C model and insurance privacy protection are differentiated
- ‚úÖ MZ-specific expertise and counseling
- ‚úÖ Patent protection prevents insurance partnership model
- ‚úÖ First-mover advantage with insurance partners

### Threat 2: AlphaNet Expands to MZ/Prevention

**Risk**: AlphaNet shifts focus from ZZ to MZ carriers
**Likelihood**: Low (Grifols conflict of interest - MZ doesn't need augmentation therapy)
**Impact**: Medium

**Mitigation**:

- ‚úÖ We have insurance partnership model (they don't)
- ‚úÖ Privacy protection (they don't offer)
- ‚úÖ Technology platform (they're service organization)
- ‚úÖ No treatment conflict of interest

### Threat 3: Insurance Companies Build In-House

**Risk**: Large insurers develop own AATD testing programs
**Likelihood**: Low (not core competency)
**Impact**: High (loss of potential partner)

**Mitigation**:

- ‚úÖ Patent protection (they need to license)
- ‚úÖ Technical complexity and compliance burden
- ‚úÖ Faster to partner than build
- ‚úÖ Our platform serves multiple insurers (economies of scale)

### Threat 4: Quest/LabCorp Launch Consumer Model

**Risk**: Clinical labs go direct-to-consumer or partner with insurers
**Likelihood**: Low (not their business model)
**Impact**: Medium

**Mitigation**:

- ‚úÖ We can partner with them as lab provider
- ‚úÖ Our value is software/platform, not lab testing
- ‚úÖ Privacy framework and insurance model are differentiated

### Threat 5: Regulatory Changes (FDA)

**Risk**: FDA reclassifies SERPINA1 as requiring PMA (not LDT)
**Likelihood**: Low-Medium (FDA focus on high-risk tests)
**Impact**: High (delays, costs)

**Mitigation**:

- ‚úÖ Work with FDA-approved lab partners
- ‚úÖ AATD testing is established (low controversy)
- ‚úÖ Clinical utility well-documented
- ‚úÖ Budget for regulatory pathways in financial model

---

## Market Positioning Strategy

### Target Positioning Statement

**For** life and health insurance companies **who want to** improve customer health outcomes and reduce long-term claims costs **while respecting genetic privacy**,

**Fair Underwriting** is a **privacy-protected genetic wellness platform** **that** enables post-policy AATD testing with patent-protected privacy guarantees.

**Unlike** traditional genetic testing companies or disease management programs, **Fair Underwriting** provides **legal protection against genetic discrimination through our patent framework, making genetic testing safe and beneficial for all stakeholders.**

---

### Positioning Pillars

1. **Privacy First**: Only platform with patent-protected insurance privacy
2. **Clinical Value**: MZ detection = actionable prevention for 2-3% of population
3. **Win-Win-Win**: Benefits customers, insurers, and society
4. **Proven Model**: Built on established Velox.AI infrastructure

---

## Competitive Response Playbook

### When Prospect Says: "We already work with [Wellness Vendor]"

**Response**:

- "Great! Fair Underwriting complements activity-tracking programs by adding genetic health insights"
- "We can integrate with [Virgin Pulse, etc.] to provide genetic testing as a wellness benefit"
- "Our AATD testing identifies the 2-3% with MZ variants who benefit most from lifestyle interventions like smoking cessation"

### When Prospect Says: "Can't we just use 23andMe?"

**Response**:

- "23andMe doesn't test for SERPINA1/AATD, which affects 1 in 25-40 people"
- "23andMe doesn't have privacy protections preventing actuarial use of genetic data"
- "Our patent framework legally protects your customers from discrimination, which 23andMe cannot provide"
- "We include genetic counseling for actionable results; 23andMe does not"

### When Prospect Says: "Our customers can get tested through Quest/LabCorp"

**Response**:

- "That requires a doctor's order, usually only after symptoms appear"
- "We enable preventive testing before irreversible damage occurs"
- "Quest/LabCorp results go to physicians and potentially to insurance records; ours are privacy-protected"
- "We partner with Quest/LabCorp as lab providers‚Äîwe add the insurance wellness model and privacy framework on top"

### When Prospect Says: "We're concerned about genetic discrimination"

**Response**:

- "That's exactly why we exist! Our patent specifically addresses this concern"
- "Claim 34 legally states insureds are NOT required to share genetic results with insurers"
- "We built a 5-level data segregation architecture ensuring you never see individual genetic data"
- "You get population-level health insights; customers get personal health insights; everyone wins"

---

## Partnership vs. Competition Decision Matrix

| Organization              | Relationship | Rationale                                                     |
| ------------------------- | ------------ | ------------------------------------------------------------- |
| **Quest/LabCorp**         | Partner      | Lab services provider, not competitive in B2B2C model         |
| **AlphaNet**              | Partner      | Referral relationship for ZZ cases needing disease management |
| **Alpha-1 Foundation**    | Partner      | Education, advocacy, medical advisor recruitment              |
| **Virgin Pulse/Wellable** | Partner      | Platform integration opportunity                              |
| **Omada Health**          | Partner      | Complementary services (coaching for MZ carriers)             |
| **23andMe/Ancestry**      | Compete      | DTC genetic testing, but different model                      |
| **Color Genomics**        | Compete      | Clinical genetic testing, some overlap                        |
| **Nebula Genomics**       | Compete      | Privacy-focused WGS, minimal overlap                          |
| **Invitae**               | Compete      | Clinical panels, but now Labcorp-owned (partnership path?)    |

---

## Ongoing Competitive Intelligence

### Monitoring Plan

**Monthly**:

- Track 23andMe, Color product updates (new genes added?)
- Monitor AlphaNet program changes
- Review FDA LDT regulations

**Quarterly**:

- Update pricing matrix
- Analyze competitor funding rounds
- Review scientific literature for new AATD research
- Assess market share changes

**Annually**:

- Complete competitive analysis refresh
- Update positioning strategy
- Revise response playbook

---

## Key Takeaways

1. **No direct competitors** exist in our specific niche (insurance-partnered, privacy-protected, AATD-focused)

2. **Primary competition is customer fear of genetic discrimination**, which our patent solves

3. **Biggest opportunities are partnerships**, not competition, with many players in the ecosystem

4. **Our moat is multi-layered**: Patent + MZ focus + B2B2C model + Privacy architecture

5. **Market timing is excellent**: MZ research is new (2018-2024), genetic testing is mainstream, insurance wellness is growing

---

**Document Owner**: Business Development / Strategy Team
**Review Frequency**: Quarterly
**Last Reviewed**: November 7, 2025
**Next Review**: February 7, 2026
